Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2023 > FDA Grants Priority Review to Roche’s Glofitamab BLA in Large B-Cell Lymphoma

FDA Grants Priority Review to Roche’s Glofitamab BLA in Large B-Cell Lymphoma

FDA Grants Priority Review to Roche’s Glofitamab BLA in Large B-Cell Lymphoma

Read also

Granules India's Hyderabad-based facility gets first U.S. FDA approval

Granules India's Hyderabad-based facility gets first U.S. FDA approval

Granules India said that its subsidiary Granules Life Sciences (GLS), located in Hyderabad, has received U.S. Food and Drug Administration (FDA) approval for a product that was the sub...

Verismo Therapeutics Presents

Verismo Therapeutics Presents

Verismo Therapeutics Presents Promising Preclinical Data at SITC 2025 for SynKIR™-110 in Solid Tumors

FDA Commissioner on lifting warnings on hormone therapy for menopause

FDA Commissioner on lifting warnings on hormone therapy for menopause

The Food and Drug Administration says it is removing the black box safety warnings from all hormone therapy creams, pills and other treatments prescribed to ease the symptoms of menopause and perimeno...

FDA grants fast track designation to drug combo for colorectal cancer

FDA grants fast track designation to drug combo for colorectal cancer

The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer, following encouraging results from a clinical trial led in part by ...